You might think this would be a year of harmony in the loose-knit coalition of groups that advocate increased funding for biomedical research. After all, they have already received a sympathetic hearing for their number-one priority: to double the budget of the National Institutes of Health (NIH) by 2002. But, as disease lobbies begin testifying this week to a House appropriations subcommittee, several groups are making aggressive public appeals for a larger slice of NIH's pie for their own areas. NIH officials say their arguments are simplistic and potentially damaging.
No takes yet. Share an insight, caveat, or question.
Eliot Marshall (1997) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: